MCID: LKM005
MIFTS: 34

Leukemia, T-Cell, Chronic

Categories: Blood diseases, Bone diseases, Cancer diseases, Immune diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Leukemia, T-Cell, Chronic

MalaCards integrated aliases for Leukemia, T-Cell, Chronic:

Name: Leukemia, T-Cell, Chronic 19 75 71
Chronic T-Cell Leukemia 19
Leukemia, T-Cell 71
T-Cell Leukemia 19

Classifications:



External Ids:

UMLS 71 C0023492 C0023494

Summaries for Leukemia, T-Cell, Chronic

GARD: 19 A slow-growing type of leukemia (blood cancer) in which too many lymphocytes are found in the bone marrow and/or blood. The T-cell is specified as the defective cell line.

MalaCards based summary: Leukemia, T-Cell, Chronic, also known as chronic t-cell leukemia, is related to adult t-cell leukemia/lymphoma and t-cell acute lymphoblastic leukemia. The drugs Zidovudine and Peginterferon alfa-2b have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, t cells and bone.

Wikipedia: 75 T-cell-prolymphocytic leukemia (T-PLL) is a mature T-cell leukemia with aggressive behavior and... more...

Related Diseases for Leukemia, T-Cell, Chronic

Diseases in the Leukemia, T-Cell, Chronic family:

Human T-Cell Leukemia Virus Type 1 Human T-Cell Leukemia Virus Type 2
Human T-Cell Leukemia Virus Type 3

Diseases related to Leukemia, T-Cell, Chronic via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 672)
# Related Disease Score Top Affiliating Genes
1 adult t-cell leukemia/lymphoma 12.0
2 t-cell acute lymphoblastic leukemia 11.9
3 human t-cell leukemia virus type 1 11.8
4 tropical spastic paraparesis 11.6
5 human t-cell leukemia virus type 2 11.6
6 t-cell adult acute lymphocytic leukemia 11.5
7 t-cell prolymphocytic leukemia 11.5
8 n syndrome 11.5
9 leukemia 11.4
10 pediatric t-cell leukemia 11.4
11 human t-cell leukemia virus type 3 11.2
12 lymphoma 11.2
13 burkitt lymphoma 11.2
14 infective dermatitis associated with htlv-1 11.2
15 adult syndrome 11.1
16 spinal cord disease 11.1
17 hereditary spastic paraplegia 11.0
18 spastic paraparesis 11.0
19 leukemia, acute lymphoblastic 10.9
20 precursor t-cell acute lymphoblastic leukemia 10.8
21 lymphoma, hodgkin, classic 10.8
22 human immunodeficiency virus type 1 10.8
23 severe combined immunodeficiency 10.7
24 immune deficiency disease 10.7
25 lymphoproliferative syndrome 10.7
26 leukemia, chronic lymphocytic 10.7
27 acquired immunodeficiency syndrome 10.7
28 fungal infectious disease 10.7
29 mycosis fungoides 10.7
30 graft-versus-host disease 10.7
31 peripheral t-cell lymphoma 10.7
32 primary cutaneous t-cell non-hodgkin lymphoma 10.7
33 hematologic cancer 10.6
34 b-cell lymphoma 10.6
35 sezary's disease 10.6
36 viral infectious disease 10.6
37 strongyloidiasis 10.6
38 uveitis 10.5
39 hairy cell leukemia 10.5
40 primary agammaglobulinemia 10.5
41 lymphoma, non-hodgkin, familial 10.5
42 acute leukemia 10.5
43 splenomegaly 10.5
44 exanthem 10.5
45 chronic bilirubin encephalopathy 10.5
46 aplastic anemia 10.5
47 pneumocystosis 10.5
48 down syndrome 10.5
49 acute graft versus host disease 10.5
50 retinoblastoma 10.5

Graphical network of the top 20 diseases related to Leukemia, T-Cell, Chronic:



Diseases related to Leukemia, T-Cell, Chronic

Symptoms & Phenotypes for Leukemia, T-Cell, Chronic

Drugs & Therapeutics for Leukemia, T-Cell, Chronic

Drugs for Leukemia, T-Cell, Chronic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 186)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zidovudine Approved Phase 4 30516-87-1 35370
2
Peginterferon alfa-2b Approved Phase 4 215647-85-1, 99210-65-8
3
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
4
Daclizumab Investigational, Withdrawn Phase 4 152923-56-3
5 Interferon alpha-2 Phase 4
6 interferons Phase 4
7 Interferon-alpha Phase 4
8 Reverse Transcriptase Inhibitors Phase 4
9 Neurotransmitter Agents Phase 4
10 Psychotropic Drugs Phase 4
11 Anticonvulsants Phase 4
12
Idarubicin Approved Phase 2, Phase 3 58957-92-9 42890
13
Decitabine Approved, Investigational Phase 3 2353-33-5 451668
14
Aclarubicin Investigational Phase 3 57576-44-0
15 Adjuvants, Immunologic Phase 3
16
homoharringtonine Phase 3 3628
17
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189
18
Clotrimazole Approved, Vet_approved Phase 1, Phase 2 23593-75-1 2812
19
Etoposide Approved Phase 2 33419-42-0 36462
20
Triamcinolone Approved, Vet_approved Phase 1, Phase 2 124-94-7 31307
21
Alemtuzumab Approved, Investigational Phase 2 216503-57-0
22
Cladribine Approved, Investigational Phase 2 4291-63-8 20279
23
Melphalan Approved Phase 2 148-82-3 4053 460612
24
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
25
Mogamulizumab Approved, Investigational Phase 2 1159266-37-1
26
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
27
Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
28
Prednisolone Approved, Vet_approved Phase 2 50-24-8 4894 5755
29
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5 1875
30
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 4159 6741
31
Everolimus Approved Phase 1, Phase 2 159351-69-6 70789204 6442177
32
Cisplatin Approved Phase 2 15663-27-1 2767 5702198 441203
33
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 43805 11947679 6857599
34
Lamivudine Approved, Investigational Phase 2 134678-17-4 60825
35
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239
36
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 5284616 6436030
37
Vindesine Approved, Investigational Phase 2 59917-39-4, 53643-48-4 40839
38
Iron Approved Phase 2 7439-89-6 29936
39
Deferasirox Approved, Investigational Phase 2 201530-41-8 214348 5493381
40
Edetate calcium disodium anhydrous Approved, Vet_approved Phase 1, Phase 2 62-33-9, 60-00-4 6049
41
Pentetic acid Approved Phase 1, Phase 2 67-43-6
42
Azacitidine Approved, Investigational Phase 2 320-67-2 9444
43
Carboplatin Approved Phase 2 41575-94-4 10339178 38904
44
Lomustine Approved, Investigational Phase 2 13010-47-4 3950
45
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
46
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
47
Venetoclax Approved, Investigational Phase 2 1257044-40-8 49846579
48
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
49
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
50
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703

Interventional clinical trials:

(show top 50) (show all 152)
# Name Status NCT ID Phase Drugs
1 HTLV Blot 2.4 Post-Market Clinical Study of Neurological Disorders and HTLV Positive Specimens Completed NCT03226119 Phase 4
2 HTLV-I Associated Adult T-cell Leukaemia/Lymphoma (ATLL) Pilot Study of Combination Therapy With CHOP-Zenapax (CHOP-daclizumab) Completed NCT01418430 Phase 4 CHOP-daclizumab
3 Prospective Study of the Molecular Characteristics of Sensitive and Resistant Disease in Patients With HTLV-I Associated Adult T Cell Leukemia Treated With Zidovudine (AZT) Plus Interferon Alpha-2b Terminated NCT00854581 Phase 4 Valproic Acid;Zidovudine
4 An Open-Label, One-Arm, Multi-Site Trial of Precision Diagnosis Directing Histone Deacetylase Inhibitor Chidamide Target Total Therapy for Adult Early T-cell Progenitor Acute Lymphoblastic Leukemia/Lymphoma Unknown status NCT03553238 Phase 2, Phase 3 Chidamide;Dexamethasone;vincristine;Cyclophosphamide;Idarubicin;Pegaspargase;Adriamycin;Methotrexate;6-Mercaptopurine;Etoposide;Cytarabine
5 An Open-Label, One-Arm, Multi-Site Trial of Precision Diagnosis Directing Histone Deacetylase Inhibitor Chidamide Total Therapy for Adult T-lymphoblastic Lymphoma/Leukemia Unknown status NCT03564704 Phase 2, Phase 3 Dexamethasone;vincristine;Cyclophosphamide;Idarubicin;Pegaspargase;Adriamycin;Methotrexate;6-mercaptopurine.;Etoposide;Cytarabine;Chidamide
6 Phase III Study of VCAP-AMP-VECP vs. Biweekly CHOP in Aggressive Adult T-cell Leukemia-lymphoma (ATLL): Japan Clinical Oncology Group Study, JCOG9801. Completed NCT00145002 Phase 3 VCAP-AMP-VECP with G-CSF and intrathecal prophylaxis;biweekly-CHOP with G-CSF and intrathecal prophylaxis
7 A Phase 3, Open Label, Single Arm, Multi-Center Study to Evaluate the Efficacy and Safety of Decitabine Combined With HAAG Regimen in Newly Diagnosed ETP-ALL/LBL, T/M-MPAL and ALL/LBL With Myeloid or Stem Cell Markers Patients Recruiting NCT04446130 Phase 3 Decitabine combined with HAAG Regimen
8 Phase I/II Study of Ruxolitinib Plus L-asparaginase, Vincristine, and Prednisone in Adult Patients With Relapsed or Refractory Early T Precursor Acute Lymphocytic Leukemia Unknown status NCT03613428 Phase 1, Phase 2 Ruxolitinib;Vincristine;Prednisone
9 A Phase II, Multi-Center Open-Label, Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell Leukemia With an Option of Long-Term Forodesine Hydrochloride (BCX-1777) Use Completed NCT00095381 Phase 2 forodesine hydrochloride (BCX-1777)
10 German Multicenter Phase II Trial to Study Effectivity and Feasibility of Alemtuzumab (MabCampath®) in T-ALL and T-Lymphoblastic Lymphomas With Minimal Residual Disease (MRD), in Refractory Relapse or in Primary Failure Completed NCT00199030 Phase 2 Alemtuzumab (MabCampath);Cladribine
11 Pilot Study of Prophylactic Dose-Escalation Donor Lymphocyte Infusion After T Cell Depleted Allogeneic Stem Cell Transplant in High Risk Patients With Hematologic Malignancies Completed NCT01839916 Phase 2
12 A Phase II Study to Evaluate the Efficacy of Oral Beclomethasone Dipropionate for Prevention of Acute GVHD After Hematopoietic Cell Transplantation With Myeloablative Conditioning Regimens Completed NCT00489203 Phase 2 beclomethasone dipropionate;placebo;tacrolimus;methotrexate
13 Phase II Trial of Nivolumab for HTLV-Associated Adult T Cell Leukemia/Lymphoma Completed NCT02631746 Phase 2
14 Phase I/II Study of RAD001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Myeloid Leukemia in Blastic-Phase, Agnogenic Myeloid Metaplasia, Chronic Lymphocytic Leukemia, T-Cell Leukemia, or Mantle Cell Lymphoma Completed NCT00081874 Phase 1, Phase 2 RAD001
15 Prolonged Mycophenolate Mofetil and Truncated Cyclosporine Postgrafting Immunosuppression to Reduce Life-Threatening GVHD After Unrelated Donor Peripheral Blood Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-Center Trial Completed NCT00078858 Phase 1, Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
16 A Phase II Study of Bendamustine (B), Etoposide (E), Dexamethasone (D), and GCSF for Peripheral Blood Hematopoietic Stem Cell Mobilization (BED) Completed NCT01110135 Phase 2 bendamustine hydrochloride;dexamethasone;etoposide
17 A Multi-Center Study of Nonmyeloablative Conditioning With TBI or Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies With Post Grafting Immunosuppression With Tacrolimus and Mycophenolate Mofetil Completed NCT00089011 Phase 2 fludarabine phosphate;mycophenolate mofetil;tacrolimus
18 Induction of Mixed Hematopoietic Chimerism in Patients Using Fludarabine, Low Dose TBI, PBSC Infusion and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil Completed NCT00006251 Phase 1, Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
19 Multi-Center, Open-Label, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL) Completed NCT01626664 Phase 2 Pralatrexate;gemcitabine plus oxaliplatin;DHAP
20 Phase II Study of the Efficacy and Toxicity of Campath-1H in the Therapy of Adult T-Cell Leukemia Completed NCT00061048 Phase 2
21 Nonmyeloablative Hematopoietic Stem Cell Transplantation for Patients With High-Risk Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Phase II Trial of Combined Immunosuppression Before and After Transplantation Completed NCT00049504 Phase 2 cyclophosphamide;fludarabine phosphate;tacrolimus;mycophenolate mofetil
22 Phase II Trial Of Induction Therapy With EPOCH Chemotherapy And Maintenance Therapy With Combivir/Interferon ALPHA-2a For HTLV-1 Associated T-Cell Non-Hodgkin's Lymphoma Completed NCT00041327 Phase 2 Etoposide;cyclophosphamide;doxorubicin hydrochloride;lamivudine;prednisone;vincristine sulfate;zidovudine
23 A Phase II Study of Oxaliplatin in Relapsed and Refractory Non-Hodgkin's Lymphoma Completed NCT00006473 Phase 2 oxaliplatin
24 A Phase II Study of Sorafenib (BAY 43-9006) in Recurrent Aggressive Non-Hodgkin's Lymphoma Completed NCT00131937 Phase 2 sorafenib tosylate
25 A Phase II Study of 506U78 in Patients With Previously Systemically Untreated Cutaneous T-cell Lymphoma (CTCL) or With Refractory or Relapsed Non-cutaneous Peripheral T-cell Lymphoma (PTCL) Completed NCT00005080 Phase 2 nelarabine
26 A Phase I/II Study of the Efficacy and Toxicity of Humanized Anti-Tac (Zenapax(Trademark)) in the Therapy of Tac-Expressing Adult T-Cell Leukemia Completed NCT00001941 Phase 1, Phase 2
27 A Phase I/II Study of the Histone Deacetylase (HDAC) Inhibitor LBH589 (Panobinostat) in Combination With mTOR Inhibitor RAD001 (Everolimus) in Patients With Relapsed Multiple Myeloma or Lymphoma Completed NCT00918333 Phase 1, Phase 2 panobinostat;everolimus
28 A Phase II Study of A-dmDT390-bisFv(UCHT1) Fusion Protein in Patients With Cutaneous T Cell Lymphoma Completed NCT00611208 Phase 2
29 Campath® [Alemtuzumab] Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class I Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies - A Multi-Center Trial Completed NCT00040846 Phase 2 fludarabine phosphate;mycophenolate mofetil;cyclosporine
30 Phase II Clinical Study of KW-0761 in Patients With CCR4-Positive Adult T-cell Leukemia-Lymphoma Completed NCT00920790 Phase 2
31 A Phase I/II Clinical Trial of the mTor Inhibitor RAD001 (Everolimus) in Combination With Lenalidomide (Revlimid) for Patients With Relapsed or Refractory Lymphoid Malignancy Completed NCT01075321 Phase 1, Phase 2 everolimus;lenalidomide
32 Campath (Alemtuzumab) Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class II Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies: A Multicenter Trial Completed NCT00118352 Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
33 Phase II Evaluation of FTI (R115777) in Treatment of Relapsed and Refractory Lymphoma Completed NCT00082888 Phase 2 Tipifarnib
34 A Phase II Study Evaluating the Efficacy of Gemcitabine, Carboplatin, and Dexamethasone and Rituximab for Previously Treated Lymphoid Malignancies Completed NCT00072514 Phase 2 gemcitabine hydrochloride;carboplatin;dexamethasone
35 Phase I/II Trial of Dose-Adjusted EPOCH Chemotherapy With Bortezomib Combined With Integrase Inhibitor Therapy for HTLV-1 Associated T-Cell Leukemia Lymphoma Completed NCT01000285 Phase 1, Phase 2 Bortezomib;Etoposide;Vincristine;Doxorubicin;Prednisone;Cyclophosphamide;Raltegravir
36 Phase II Study of MK-2206 in Patients With Relapsed Lymphoma Completed NCT01258998 Phase 2 Akt inhibitor MK2206
37 A Phase II Study of the Histone Deacetylase (HDAC) Inhibitor LBH589 (Panobinostat) in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Completed NCT01261247 Phase 2 panobinostat
38 Phase II Study of Therapy With IMTOX-25 in Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma Completed NCT01378871 Phase 2 IMTOX-25
39 A Phase II Study of Lenalidomide in Patients With Relapsed or Refractory HTLV-1 Associated Adult T Cell Leukemia/Lymphoma Completed NCT01274533 Phase 2 Lenalidomide
40 Multicenter, Randomized, Open-label, Parallel-group Study to Compare mLSG15 + KW-0761 to mLSG15 in Subjects With CCR4-positive Adult T-cell Leukemia-lymphoma (Untreated Primary Disease) Completed NCT01173887 Phase 2 VCAP/AMP/VECP(mLSG15)
41 A Phase II Trial of Reduced Intensity Allogeneic Stem Cell Transplantation With Fludarabine, Melphalan and Low Dose Total Body Irradiation Completed NCT01529827 Phase 2 fludarabine phosphate;melphalan;tacrolimus;mycophenolate mofetil;methotrexate
42 High-dose Busulfan, High-dose Cyclophosphamide, and Allogeneic Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndromes, Multiple Myeloma and Lymphoma Completed NCT01177371 Phase 2 busulfan;cyclophosphamide;methylprednisolone;methotrexate;cyclosporine
43 Phase I/II Trial Evaluating the Safety and Efficacy of Ruxolitinib in Patients With Smoldering and Chronic Adult T-cell Leukemia (ATL) Completed NCT01712659 Phase 1, Phase 2 Ruxolitinib;ruxolitinib
44 Phase II Trial of the Aurora Kinase A Inhibitor MLN8237, in Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma Completed NCT01466881 Phase 2 Alisertib
45 A Phase II Study to Evaluate the Efficacy of Posttransplant Cyclophosphamide for Prevention of Chronic Graft-versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation Completed NCT01427881 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;busulfan
46 A Phase 2, Multicenter, Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma Completed NCT01724177 Phase 2 Lenalidomide
47 A Phase 1b/2a Study of ABT-888 in Combination With Bendamustine +/- Rituximab in Lymphoma, Multiple Myeloma and Solid Tumors Completed NCT01326702 Phase 1, Phase 2 Bendamustine Hydrochloride;Veliparib
48 Impact of Intervention With Deferasirox on the Immune Function of Patients With Hematologic Diseases and Transfusion-Related Iron Overload Completed NCT01273766 Phase 2 deferasirox
49 PHASE I/II STUDY OF TAC-EXPRESSING ADULT T-CELL LEUKEMIA (ATL) WITH YTTRIUM-90 (90Y)-RADIOLABELED HUMANIZED ANTI-TAC AND CALCIUM-DTPA Completed NCT00019227 Phase 1, Phase 2 pentetic acid calcium
50 A Phase II Trial of Belinostat as Consolidation Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma Recruiting NCT02737046 Phase 2 Belinostat;Zidovudine;Interferon-Alfa-2b;Pegylated Interferon-Alfa-2b

Search NIH Clinical Center for Leukemia, T-Cell, Chronic

Genetic Tests for Leukemia, T-Cell, Chronic

Anatomical Context for Leukemia, T-Cell, Chronic

Organs/tissues related to Leukemia, T-Cell, Chronic:

MalaCards : Bone Marrow, T Cells, Bone, Liver, Spleen, Skin, Myeloid

Publications for Leukemia, T-Cell, Chronic

Articles related to Leukemia, T-Cell, Chronic:

(show top 50) (show all 9261)
# Title Authors PMID Year
1
ANK Therapeutic Prospects and Usefulness of PD-L1 and NK Activity as Biomarkers for Predicting Treatment Efficacy Revealed from the Treatment Course of Patients with HTLV-1-Associated Bronchioloalveolar Disease. 62
36282976 2023
2
Discovery of Aptamers Against Cell Surface Markers Using Ligand-Guided Selection. 62
36156771 2023
3
Genome-wide methylation analysis of pre-pregnancy women in hypothyroidism. 62
33455507 2022
4
Increasing horizontal transmission of human T-cell leukemia virus type 1 in adolescents and young adults in Japan. 62
36370501 2022
5
Regulation of human T-cell leukemia virus type 1 antisense promoter by myocyte enhancer factor-2C in the context of adult T-cell leukemia and lymphoma. 62
35615924 2022
6
Molecular insight into the study of adult T-cell leukemia/lymphoma (ATLL): Ten-year studies on HTLV-1 associated diseases in an endemic region. 62
36108787 2022
7
Clinical activity of 9-ING-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, in refractory adult T-Cell leukemia/lymphoma. 62
35815408 2022
8
Prognostic role of controlling nutritional status score in hematological malignancies. 62
35622088 2022
9
Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical study. 62
36151216 2022
10
HTLV-I associated bronchioloalveolar disorder (HABA): disease concept and differential diagnosis of an unsolved disease entity. 62
36437745 2022
11
Investigation of berberine and its derivatives in Sars Cov-2 main protease structure by molecular docking, PROTOX-II and ADMET methods: in machine learning and in silico study. 62
36369803 2022
12
Endothelial function testing before conditioning therapy is useful for predicting transplant-related complications after allogeneic hematopoietic cell transplantation. 62
36436130 2022
13
CARD11 mutation and HBZ expression induce lymphoproliferative disease and adult T-cell leukemia/lymphoma. 62
36446869 2022
14
Cholesterol metabolism and lipid droplet vacuoles; a potential target for the therapy of aggressive lymphoma. 62
36436934 2022
15
A frequent PLCγ1 mutation in adult T-cell leukemia/lymphoma determines functional properties of the malignant cells. 62
36442790 2022
16
Landscape of immunoglobulin heavy chain gamma gene class switch recombination in patients with adult T-cell leukemia-lymphoma. 62
36420800 2022
17
Radiation Recall Dermatitis after Donor Lymphocyte Infusion for Adult T cell Leukemia Lymphoma post Allogeneic Stem Cell Transplant. 62
36347452 2022
18
Circulating clover-leaf cells presenting in acute-type adult T-cell leukemia-lymphoma. 62
36467847 2022
19
Pseudo-progression of adult T-cell leukemia-lymphoma after cord blood transplantation. 62
35734929 2022
20
A therapeutically targetable NOTCH1-SIRT1-KAT7 axis in T-cell Leukemia. 62
36322781 2022
21
Genome-wide CRISPR screens identify CD48 defining susceptibility to NK cytotoxicity in peripheral T-cell lymphomas. 62
35921533 2022
22
Ancestral APOBEC3B Nuclear Localization Is Maintained in Humans and Apes and Altered in Most Other Old World Primate Species. 62
36374108 2022
23
Identification of the OA-related metabolism-related genes, corresponding transcription factors, relevant pathways, and specific bioactive small molecules. 62
36152536 2022
24
Rab11-FIP1C Is Dispensable for HIV-1 Replication in Primary CD4+ T Cells, but Its Role Is Cell Type Dependent in Immortalized Human T-Cell Lines. 62
36354340 2022
25
Potential Anti-Tumor Activity of Nardoguaianone L Isolated from Nardostachys jatamansi DC. in SW1990 Cells. 62
36364317 2022
26
Identification of differentially expressed genes and pathways in diquat and paraquat poisoning using bioinformatics analysis. 62
35392760 2022
27
Establishment of a Cynomolgus Macaque Model of Human T-Cell Leukemia Virus Type 1 (HTLV-1) Infection by Direct Inoculation of Adult T-Cell Leukemia Patient-Derived Cell Lines for HTLV-1 Infection. 62
36314828 2022
28
Acute type adult T-cell leukemia cells proliferate in the lymph nodes rather than in peripheral blood. 62
35459881 2022
29
Majocchi Granuloma in a Patient with Adult T-cell Leukemia. 62
36409384 2022
30
Epigenome-wide analysis of T-cell large granular lymphocytic leukemia identifies BCL11B as a potential biomarker. 62
36376973 2022
31
VEGF Polymorphism rs3025039 and Human T-Cell Leukemia Virus 1 (HTLV-1) Infection among Older Japanese Individuals: A Cross-Sectional Study. 62
36290496 2022
32
HTLV infection in Brazil's second-largest indigenous reserve. 62
36202887 2022
33
Live attenuated VZV vaccination induces antitumor immunity in ATLL patients. 62
36181532 2022
34
Validation of the iATL-PI prognostic index in therapeutic decision-making for patients with smoldering and chronic ATL: a multicenter study. 62
36308678 2022
35
Clinicopathological analysis of immunohistochemical expression of immune checkpoint molecules in follicular lymphoma. 62
35122292 2022
36
Primary Effusion Lymphoma-like ATL Developing During Hemodialysis. 62
36261387 2022
37
Diagnosis and Early Prediction of Lymphoma Using High-Throughput Clonality Analysis of Bovine Leukemia Virus-Infected Cells. 62
36227090 2022
38
Gamma-secretase inhibitor does not induce cytotoxicity in adult T-cell leukemia cell lines despite NOTCH1 expression. 62
36243685 2022
39
Identification of potential crucial genes and key pathways shared in Inflammatory Bowel Disease and cervical cancer by machine learning and integrated bioinformatics. 62
36049413 2022
40
Various types of electrochemical biosensors for leukemia detection and therapeutic approaches. 62
35588855 2022
41
Regulation of Retroviral and SARS-CoV-2 Protease Dimerization and Activity through Reversible Oxidation. 62
36290777 2022
42
The importance of the clinical classification of adult T-cell leukemia/lymphoma (ATLL) in the prognosis. 62
36260617 2022
43
[Clinical Study of Chemotherapy Combined with Antivirals for Adult T-cell Leukemia/Lymphoma]. 62
36208242 2022
44
ETS1 is a novel transcriptional regulator of adult T-cell leukemia/lymphoma of North American descent. 62
35675522 2022
45
Particularities of Neurological Manifestations in Adult T-Cell Leukemia/Lymphoma: Need for a Multidisciplinary Approach-A Narrative Review. 62
36363509 2022
46
TCL-150 Outcome of Stem Cell Transplantation in HTLV-1-Associated North American Adult T-Cell Leukemia/Lymphoma. 62
36164124 2022
47
Signaling factors potentially associated to the pathogenesis of Adult T-cell leukemia /lymphoma: A network-analysis and novel findings assessment. 62
35868352 2022
48
Valemetostat: First approval as a dual inhibitor of EZH1/2 to treat adult T-cell leukemia/lymphoma. 62
36310058 2022
49
Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia/lymphoma. 62
35417939 2022
50
The Molecular Interplay between Human Oncoviruses and Telomerase in Cancer Development. 62
36358677 2022

Variations for Leukemia, T-Cell, Chronic

Expression for Leukemia, T-Cell, Chronic

Search GEO for disease gene expression data for Leukemia, T-Cell, Chronic.

Pathways for Leukemia, T-Cell, Chronic

GO Terms for Leukemia, T-Cell, Chronic

Sources for Leukemia, T-Cell, Chronic

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....